Superion棘突间撑开器治疗中度腰椎管狭窄症:4年结果
该研究从美国食品药品监督管理局(FDA)器械豁免随机对照试验中提取Superion 4年数据,评估中度腰椎管狭窄症患者接受微创独立棘突间撑开减压的远期疗效。4年随访时122例中89例(73%)提供完整临床评估,84.3%的患者在Zurich跛行问卷(ZCQ)至少2个维度达到临床成功,各维度应答率与基线改善幅度均较明显。作者结论认为Superion可提供长期、持久的间歇性神经源性跛行症状缓解。
要点
- 4年随访时89/122例(73%)完成评估,84.3%(75/89)在ZCQ至少2个维度达临床成功。
- ZCQ症状严重度、躯体功能和患者满意度应答率分别为83%、79%和87%。
- 腿痛和背痛视觉模拟量表(VAS)应答率分别为78%和66%,Oswestry功能障碍指数(ODI)应答率为62%。
核心结论
- 作者结论认为,Superion装置的微创植入可为中度腰椎管狭窄症患者的间歇性神经源性跛行提供长期、持久的症状缓解。
研究设计与样本
- 数据来自美国食品药品监督管理局(FDA)器械豁免的随机对照试验,提取Superion 4年数据。
- 入组患者为经背部屈曲可缓解的间歇性神经源性跛行、且至少6个月非手术治疗失败者。
- 4年随访时122例中89例(73%)提供完整临床结局评估。
主要发现
- 4年时89例中75例(84.3%)在3个ZCQ维度中至少2个达到临床成功。
- ZCQ症状严重度、躯体功能和患者满意度应答率分别为83%(74/89)、79%(70/89)和87%(77/89)。
- 腿痛和背痛VAS应答率分别为78%(67/86)和66%(57/86),ODI应答率为62%(55/89)。
- 较基线改善百分比分别为ZCQ症状严重度41%、ZCQ躯体功能40%、腿痛VAS 69%、背痛VAS 61%、ODI 61%(原文此处腿痛与背痛改善百分比的顺序与常见对应关系可能不一致,照录原文数值)。
- 组内效应量均分类为非常大(>1.0):ZCQ症状严重度1.49、ZCQ躯体功能1.65、腿痛VAS 1.42、背痛VAS 1.12、ODI 1.46。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine 4-year clinical outcomes in patients with moderate lumbar spinal stenosis treated with minimally invasive stand-alone interspinous process decompression using the Superion device. METHODS: The 4-year Superion data were extracted from a randomized, controlled Food and Drug Administration investigational device exemption trial. Patients with intermittent neurogenic claudication relieved with back flexion who failed at least 6 months of nonsurgical management were enrolled. Outcomes included Zurich Claudication Questionnaire (ZCQ) symptom severity (ss), physical function (pf) and patient satisfaction (ps) subdomains, leg and back pain visual analog scale (VAS), and Oswestry Disability Index (ODI). At 4-year follow-up, 89 of the 122 patients (73%) provided complete clinical outcome evaluations. RESULTS: At 4 years after index procedure, 75 of 89 patients with Superion (84.3%) demonstrated clinical success on at least 2 of 3 ZCQ domains. Individual component responder rates were 83% (74/89), 79% (70/89), and 87% (77/89) for ZCQss, ZCQpf, and ZCQps; 78% (67/86) and 66% (57/86) for leg and back pain VAS; and 62% (55/89) for ODI. Patients with Superion also demonstrated percentage improvements over baseline of 41%, 40%, 73%, 69%, and 61% for ZCQss, ZCQpf, leg pain VAS, back pain VAS, and ODI. Within-group effect sizes all were classified as very large (>1.0): 1.49, 1.65, 1.42, 1.12, and 1.46 for ZCQss, ZCQpf, leg pain VAS, back pain VAS, and ODI. CONCLUSIONS: Minimally invasive implantation of the Superion device provides long-term, durable relief of symptoms of intermittent neurogenic claudication for patients with moderate lumbar spinal stenosis.
引用
- Nunley PD, Patel VV, Orndorff DG, et al. Superion Interspinous Spacer Treatment of Moderate Spinal Stenosis: 4-Year Results. World Neurosurg. 2017. PMID: 28479526. doi:10.1016/j.wneu.2017.04.163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。